SLC22A16 and diffuse large B-cell lymphoma: To determine whether expression of SLC22A16 would have an impact on doxorubicin transport, we overexpressed either a control or a HA-tagged SLC22A16 in OCI-Ly7 DLBCL cells, which do not express endogenous SLC22A16 (Figure 5a).